PEPFAR and AstraZeneca launch partnership across HIV and hypertension services in Africa

AstraZenecaThe U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and biopharmaceutical company AstraZeneca have announced a $10 million (subject to the availability of funds), five-year global public-private partnership that will expand access to HIV/AIDS and hypertension services by offering them in an integrated manner at existing PEPFAR-supported HIV/AIDS sites, beginning in Kenya.

The new partnership, which supports the achievement of U.N. Sustainable Development Goal 3 (good health and well-being), is designed to address these challenges head-on by optimizing existing HIV/AIDS service delivery infrastructure and more specifically enhancing services for men aged 25-50. For AstraZeneca, PEPFAR's sizable patient reach presents an opportunity to screen for hypertension during clinical triage; for PEPFAR, the ability to make hypertension screening available to men alongside HIV/AIDS services supports efforts to identify harder-to-reach patients for HIV testing, specifically males aged 25-50, and provide appropriate referral to HIV/AIDS treatment. Through joint implementation, both programs will increase their impact and leverage existing program infrastructure to engage new patients in lifesaving treatment and care.

Mark Mallon, EVP International, member of the Senior Executive Team and Healthy Heart Africa (HHA) sponsor at AstraZeneca, said: "AstraZeneca shares PEPFAR's vision of improving the health and lives of underserved communities in sub-Saharan Africa. Increasing rates of hypertension and cardiovascular disease in the region threaten individuals, families and communities, and burden already-stressed health systems. We are honoured and proud to join with PEPFAR to improve access to vital testing and treatment which help stem the tide of both hypertension and HIV/AIDS."

Ambassador Deborah L. Birx, M.D., U.S. Global AIDS Coordinator and Special Representative for Global Health Diplomacy, said: "Together, we have made remarkable progress in the global response to HIV/AIDS. Yet, we need innovative approaches to better identify and serve harder to reach populations, including men, who too often only present for care when they are very ill. Through this new partnership with AstraZeneca we will enhance our ability to deliver earlier and more effective HIV/AIDS testing and treatment for working-age men in two high-prevalence counties in Kenya."

Data show that men often access HIV/AIDS testing and treatment at far lower rates than do women. For example, according to the most recent Kenya AIDS Indicator Survey, 79.8% of women surveyed had received an HIV test whereas only 62.5% of men had received one. This significant gender disparity leads to HIV-infected men entering care with more advanced disease, being less likely to receive lifesaving antiretroviral therapy (ART), and having higher mortality than HIV-infected women. Late diagnosis also results in missed opportunities for HIV prevention, including early ART initiation, resulting in ongoing transmission to previously uninfected partners.

AstraZeneca created Healthy Heart Africa (HHA) to support national governments in Africa in testing and scaling effective models of hypertension care, including treatment through access to discounted medicines. Since the program started in 2014, HHA and partners have screened almost 2 million people, trained more than 3,000 healthcare workers, and activated over 400 health facilities to provide hypertension services. HHA has identified new strategies for bringing hard-to-reach populations into hypertension care, including men between the ages of 25 and 50.

Hypertension and cardiovascular disease are two of the largest drivers of non-communicable diseases (NCDs) across Africa. Prevalence of hypertension in Africa has increased significantly over the past three decades. In 2000, there were approximately 80 million adults with hypertension in sub-Saharan Africa. Current epidemiological data suggest that this figure will rise to 150 million by 2025. In addition, evidence indicates that complications related to hypertension, in particular stroke and heart failure, are increasingly common in this region.

Launching in October 2016 with a one-year pilot program in Western Kenya, the partnership, in collaboration with the Kenyan Ministry of Health will leverage PEPFAR's existing HIV/AIDS infrastructure in Homa Bay and Kisumu. This area was identified due to the high burden for all patients but particularly working-age males who have not yet been reached by current HIV/AIDS programming. Longer term, the partnership aims to extend to other areas where the burden of both HIV/AIDS and hypertension is particularly high.

Subject to the availability of funds, it is intended that the initial pilot will be implemented by PATH, a Seattle-based PEPFAR partner with extensive expertise implementing both HIV and NCD programming. PATH is the leading implementing partner for the large-scale USAID APHIAplus programme, which integrates and improves health service delivery in Western and Nyanza regions of Kenya.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

About PEPFAR
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) was launched in 2003 and represents America's commitment to saving lives and the shared responsibility of all global partners to achieve an AIDS-free generation. PEPFAR is the largest effort by any nation to combat a single disease. With the generous support of the American people, the U.S. government has committed more than $70 billion to bilateral HIV/AIDS programs; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and bilateral tuberculosis programs.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...